A helpful mnemonic for remembering transfusion reactions is Got a bad unit. Each letter represents a potential complication:

G – Graft vs. Host disease
O – Overload
T – Thrombocytopenia
A – Alloimmunization
B – Blood pressure unstable
A – Acute hemolytic reaction
D – Delayed hemolytic reaction
U – Urticaria
N – Neutrophilia
I – Infection
T – Transfusion-associated lung injury

Graft vs. Host disease occurs when the patient’s own lymphocytes are similar to the donor’s lymphocytes, causing severe complications. Thrombocytopenia may occur a few days after transfusion and may resolve on its own. Patients with IGA antibodies require IgA deficient blood transfusions.

Blood product transfusion complications can be categorized into immunological, infective, and other complications. Immunological complications include acute haemolytic reactions, non-haemolytic febrile reactions, and allergic/anaphylaxis reactions. Infective complications may arise due to transmission of vCJD, although measures have been taken to minimize this risk. Other complications include transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), hyperkalaemia, iron overload, and clotting.

Non-haemolytic febrile reactions are thought to be caused by antibodies reacting with white cell fragments in the blood product and cytokines that have leaked from the blood cell during storage. These reactions may occur in 1-2% of red cell transfusions and 10-30% of platelet transfusions. Minor allergic reactions may also occur due to foreign plasma proteins, while anaphylaxis may be caused by patients with IgA deficiency who have anti-IgA antibodies.

Acute haemolytic transfusion reaction is a serious complication that results from a mismatch of blood group (ABO) which causes massive intravascular haemolysis. Symptoms begin minutes after the transfusion is started and include a fever, abdominal and chest pain, agitation, and hypotension. Treatment should include immediate transfusion termination, generous fluid resuscitation with saline solution, and informing the lab. Complications include disseminated intravascular coagulation and renal failure.

TRALI is a rare but potentially fatal complication of blood transfusion that is characterized by the development of hypoxaemia/acute respiratory distress syndrome within 6 hours of transfusion. On the other hand, TACO is a relatively common reaction due to fluid overload resulting in pulmonary oedema. As well as features of pulmonary oedema, the patient may also be hypertensive, a key difference from patients with TRALI.

Generalized lymphadenopathy may be caused by the Epstein-Barr Virus, which can also be linked to splenomegaly. This enlargement has been known to result in spontaneous rupture.

The Anatomy and Function of the Spleen

The spleen is an organ located in the left upper quadrant of the abdomen. Its size can vary depending on the amount of blood it contains, but the typical adult spleen is 12.5cm long and 7.5cm wide, with a weight of 150g. The spleen is almost entirely covered by peritoneum and is separated from the 9th, 10th, and 11th ribs by both diaphragm and pleural cavity. Its shape is influenced by the state of the colon and stomach, with gastric distension causing it to resemble an orange segment and colonic distension causing it to become more tetrahedral.

The spleen has two folds of peritoneum that connect it to the posterior abdominal wall and stomach: the lienorenal ligament and gastrosplenic ligament. The lienorenal ligament contains the splenic vessels, while the short gastric and left gastroepiploic branches of the splenic artery pass through the layers of the gastrosplenic ligament. The spleen is in contact with the phrenicocolic ligament laterally.

The spleen has two main functions: filtration and immunity. It filters abnormal blood cells and foreign bodies such as bacteria, and produces properdin and tuftsin, which help target fungi and bacteria for phagocytosis. The spleen also stores 40% of platelets, utilizes iron, and stores monocytes. Disorders of the spleen include massive splenomegaly, myelofibrosis, chronic myeloid leukemia, visceral leishmaniasis, malaria, Gaucher’s syndrome, portal hypertension, lymphoproliferative disease, haemolytic anaemia, infection, infective endocarditis, sickle-cell, thalassaemia, and rheumatoid arthritis.

Invasion is a characteristic of invasive disease and is not typically seen in cases of DCIS. However, angiogenesis may be present in cases of high grade DCIS.

Characteristics of Malignancy in Histopathology

Histopathology is the study of tissue architecture and cellular changes in disease. In malignancy, there are several distinct characteristics that differentiate it from normal tissue or benign tumors. These features include abnormal tissue architecture, coarse chromatin, invasion of the basement membrane, abnormal mitoses, angiogenesis, de-differentiation, areas of necrosis, and nuclear pleomorphism.

Abnormal tissue architecture refers to the disorganized and irregular arrangement of cells within the tissue. Coarse chromatin refers to the appearance of the genetic material within the nucleus, which appears clumped and irregular. Invasion of the basement membrane is a hallmark of invasive malignancy, as it indicates that the cancer cells have broken through the protective layer that separates the tissue from surrounding structures. Abnormal mitoses refer to the process of cell division, which is often disrupted in cancer cells. Angiogenesis is the process by which new blood vessels are formed, which is necessary for the growth and spread of cancer cells. De-differentiation refers to the loss of specialized functions and characteristics of cells, which is common in cancer cells. Areas of necrosis refer to the death of tissue due to lack of blood supply or other factors. Finally, nuclear pleomorphism refers to the variability in size and shape of the nuclei within cancer cells.

Overall, these characteristics are important for the diagnosis and treatment of malignancy, as they help to distinguish cancer cells from normal tissue and benign tumors. By identifying these features in histopathology samples, doctors can make more accurate diagnoses and develop more effective treatment plans for patients with cancer.

The primary cause of hypercalcemia in multiple myeloma is increased osteoclast activity in response to cytokines released by the myeloma cells. This neoplasm of bone marrow plasma cells is most commonly seen in males aged 60-70 years old, which fits the demographic of the patient in this scenario. It is important to investigate patients presenting with hypercalcemia for an underlying diagnosis of multiple myeloma. Decreased osteoblast function, elevated PTH-rP levels, and impaired renal function are less contributing factors to hypercalcemia in myeloma compared to increased osteoclastic activity. Although impaired renal function is commonly seen in multiple myeloma, it is not stated whether this patient has decreased renal function.

Understanding Multiple Myeloma: Features and Investigations

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is most commonly found in patients aged 60-70 years. The disease is characterized by a range of symptoms, which can be remembered using the mnemonic CRABBI. These include hypercalcemia, renal damage, anemia, bleeding, bone lesions, and increased susceptibility to infection. Other features of multiple myeloma include amyloidosis, carpal tunnel syndrome, neuropathy, and hyperviscosity.

To diagnose multiple myeloma, a range of investigations are required. Blood tests can reveal anemia, renal failure, and hypercalcemia. Protein electrophoresis can detect raised levels of monoclonal IgA/IgG proteins in the serum, while bone marrow aspiration can confirm the diagnosis if the number of plasma cells is significantly raised. Imaging studies, such as whole-body MRI or X-rays, can be used to detect osteolytic lesions.

The diagnostic criteria for multiple myeloma require one major and one minor criteria or three minor criteria in an individual who has signs or symptoms of the disease. Major criteria include the presence of plasmacytoma, 30% plasma cells in a bone marrow sample, or elevated levels of M protein in the blood or urine. Minor criteria include 10% to 30% plasma cells in a bone marrow sample, minor elevations in the level of M protein in the blood or urine, osteolytic lesions, or low levels of antibodies in the blood. Understanding the features and investigations of multiple myeloma is crucial for early detection and effective treatment.

The correct diagnosis for the patient is sideroblastic anaemia, which is characterized by hypochromic microcytic anaemia, high levels of ferritin iron and transferrin saturation, and basophilic stippling of red blood cells. This condition is caused by vitamin B6 deficiency due to frequent alcohol consumption, leading to abnormal heme production. The peripheral smear shows basophilic stippling of red blood cells, and there is iron overload causing iron deposition in the bone marrow, observed as increased staining with Prussian blue.

Anaemia of chronic disease, iron deficiency anaemia, and aplastic anaemia are incorrect diagnoses. Anaemia of chronic disease is usually normocytic normochromic and has significantly low levels of folate, B12, and iron while ferritin is high. Iron deficiency anaemia may be microcytic hypochromic, but serum iron, ferritin, and transferrin levels would be reduced. Aplastic anaemia presents with pancytopenia and is rarely found in the given age group.

Understanding Sideroblastic Anaemia

Sideroblastic anaemia is a medical condition that occurs when red blood cells fail to produce enough haem, which is partly synthesized in the mitochondria. This results in the accumulation of iron in the mitochondria, forming a ring around the nucleus known as a ring sideroblast. The condition can be either congenital or acquired.

The congenital cause of sideroblastic anaemia is delta-aminolevulinate synthase-2 deficiency. On the other hand, acquired causes include myelodysplasia, alcohol, lead, and anti-TB medications.

To diagnose sideroblastic anaemia, doctors may conduct a full blood count, iron studies, and a blood film. The results may show hypochromic microcytic anaemia, high ferritin, high iron, high transferrin saturation, and basophilic stippling of red blood cells. A bone marrow test may also be done, and Prussian blue staining can reveal ringed sideroblasts.

Management of sideroblastic anaemia is mainly supportive, and treatment focuses on addressing any underlying cause. Pyridoxine may also be prescribed to help manage the condition.

In summary, sideroblastic anaemia is a condition that affects the production of haem in red blood cells, leading to the accumulation of iron in the mitochondria. It can be congenital or acquired, and diagnosis involves various tests. Treatment is mainly supportive, and addressing any underlying cause is crucial.

CLL is linked to warm autoimmune haemolytic anaemia.

Complications of Chronic Lymphocytic Leukaemia

Chronic lymphocytic leukaemia (CLL) is a type of cancer that affects the blood and bone marrow. It can lead to various complications, including anaemia, hypogammaglobulinaemia, and warm autoimmune haemolytic anaemia. Patients with CLL may also experience recurrent infections due to their weakened immune system. However, one of the most severe complications of CLL is Richter’s transformation.

Richter’s transformation occurs when CLL cells transform into a high-grade, fast-growing non-Hodgkin’s lymphoma. This transformation can happen when the leukaemia cells enter the lymph nodes. Patients with Richter’s transformation often become unwell very suddenly and may experience symptoms such as lymph node swelling, fever without infection, weight loss, night sweats, nausea, and abdominal pain.

It is essential for patients with CLL to be aware of the potential complications and to seek medical attention if they experience any concerning symptoms. Regular check-ups and monitoring can also help detect any changes in the condition early on, allowing for prompt treatment and management.

The medulla of the thymus contains concentric rings of epithelial cells known as Hassall’s corpuscles.

The Thymus Gland: Development, Structure, and Function

The thymus gland is an encapsulated organ that develops from the third and fourth pharyngeal pouches. It descends to the anterior superior mediastinum and is subdivided into lobules, each consisting of a cortex and a medulla. The cortex is made up of tightly packed lymphocytes, while the medulla is mostly composed of epithelial cells. Hassall’s corpuscles, which are concentrically arranged medullary epithelial cells that may surround a keratinized center, are also present.

The inferior parathyroid glands, which also develop from the third pharyngeal pouch, may be located with the thymus gland. The thymus gland’s arterial supply comes from the internal mammary artery or pericardiophrenic arteries, while its venous drainage is to the left brachiocephalic vein. The thymus gland plays a crucial role in the development and maturation of T-cells, which are essential for the immune system’s proper functioning.

The Factor V Leiden mutation causes activated protein C resistance, resulting in excess clotting due to inefficient inactivation of factor V. This is the correct answer.

Antiphospholipid antibodies binding to plasma membranes is not the correct answer as it is a mechanism of blood clot formation in antiphospholipid syndrome (APS).

High levels of platelets in the blood is also not the correct answer as it is not implicated in Factor V Leiden. Thrombocytosis, or high levels of platelets, can lead to clots but is not related to this mutation.

Low levels of factor V in the blood is also not the correct answer as factor V deficiency is a rare inherited bleeding disorder, not a clotting disorder. It is a form of haemophilia.

Understanding Factor V Leiden

Factor V Leiden is a common inherited thrombophilia, affecting around 5% of the UK population. It is caused by a mutation in the Factor V Leiden protein, resulting in activated factor V being inactivated 10 times more slowly by activated protein C than normal. This leads to activated protein C resistance, which increases the risk of venous thrombosis. Heterozygotes have a 4-5 fold risk of venous thrombosis, while homozygotes have a 10 fold risk, although the prevalence of homozygotes is much lower at 0.05%.

Despite its prevalence, screening for Factor V Leiden is not recommended, even after a venous thromboembolism. This is because a previous thromboembolism itself is a risk factor for further events, and specific management should be based on this rather than the particular thrombophilia identified.

Other inherited thrombophilias include Prothrombin gene mutation, Protein C deficiency, Protein S deficiency, and Antithrombin III deficiency. The table below shows the prevalence and relative risk of venous thromboembolism for each of these conditions.

Overall, understanding Factor V Leiden and other inherited thrombophilias can help healthcare professionals identify individuals at higher risk of venous thrombosis and provide appropriate management to prevent future events.

Condition | Prevalence | Relative risk of VTE
— | — | —
Factor V Leiden (heterozygous) | 5% | 4
Factor V Leiden (homozygous) | 0.05% | 10
Prothrombin gene mutation (heterozygous) | 1.5% | 3
Protein C deficiency | 0.3% | 10
Protein S deficiency | 0.1% | 5-10
Antithrombin III deficiency | 0.02% | 10-20

Chronic Lymphocytic Leukaemia (CLL) Prognostic Indicators

Chronic lymphocytic leukaemia (CLL) is a type of cancer that affects the blood and bone marrow. Patients with CLL often have genetic mutations, with trisomy 12 being a bad prognostic indicator. ZAP-70, a tyrosine kinase involved in cell signalling, is also measured in CLL patients, and high expression is associated with a poor prognosis. On the other hand, lactate dehydrogenase (LDH) is a marker of tumour burden, and a normal level suggests less tumour bulk, which is a good prognostic marker.

Many patients with CLL may not require treatment and may die with the disease rather than from it. It is often diagnosed in asymptomatic patients who undergo blood tests for other reasons. Treating the disease too early may actually lead to a worse outcome than monitoring the patient initially. Therefore, patients who do not need to start treatment immediately have a more favourable outlook.

B cells in secondary lymphoid tissue undergo somatic hypermutation when they recognise an antigen. This process fine-tunes antibody specificity, and cells that have undergone somatic hypermutation are more mature. If CLL arises from one of these cells, it is associated with a more favourable prognosis. these prognostic indicators can help healthcare professionals determine the best course of treatment for patients with CLL.

Filgrastim is a medication that stimulates the growth of granulocytes and is commonly used to treat neutropenia. In the case of a patient with a history of fever, low blood pressure, and tachycardia, it is likely that they have developed sepsis, which is a common complication in patients receiving chemotherapy. The main treatment for sepsis is fluid resuscitation and broad-spectrum antibiotics. While filgrastim is not a direct treatment for sepsis, it can be used to address leukopenia caused by chemotherapy, aplastic anemia, and congenital neutropenia.

Darbepoetin is a medication that mimics the effects of erythropoietin and is commonly used to treat anemia, particularly in patients with renal failure.

Eltrombopag is a medication that activates the TPO receptor and is often used to treat autoimmune thrombocytopenia.

IFN-γ is a medication used to treat chronic granulomatous disease.

Granulocyte-Colony Stimulating Factors for Neutropenia

Granulocyte-colony stimulating factors (G-CSFs) are synthetic versions of a natural protein that stimulates the production of white blood cells called neutrophils. These drugs are used to increase neutrophil counts in patients who are neutropenic, meaning they have abnormally low levels of neutrophils. Neutropenia can occur as a side effect of chemotherapy or radiation therapy, or due to other factors such as infections or autoimmune disorders.

Recombinant human G-CSFs, such as filgrastim and perfilgrastim, are commonly used to treat neutropenia. These drugs work by stimulating the bone marrow to produce more neutrophils, which can help prevent infections and other complications associated with low white blood cell counts. G-CSFs are typically administered by injection, either subcutaneously or intravenously.

Overall, G-CSFs are an important tool in the management of neutropenia, particularly in patients undergoing chemotherapy or other treatments that can suppress the immune system. By boosting neutrophil production, these drugs can help reduce the risk of infections and improve outcomes for patients with compromised immune function.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

The Batson venous plexus is responsible for the majority of bony metastases in cancers commonly associated with bone metastasis, including advanced prostate cancer. This valveless venous plexus has also been linked to bone metastasis in bladder, breast, and, to a lesser extent, lung cancer.

Bone Metastases: Common Tumours and Sites

Bone metastases occur when cancer cells from a primary tumour spread to the bones. The most common tumours that cause bone metastases are prostate, breast, and lung cancer, with prostate cancer being the most frequent. The most common sites for bone metastases are the spine, pelvis, ribs, skull, and long bones.

Aside from bone pain, other features of bone metastases may include pathological fractures, hypercalcaemia, and raised levels of alkaline phosphatase (ALP). Pathological fractures occur when the bone weakens due to the cancer cells, causing it to break. Hypercalcaemia is a condition where there is too much calcium in the blood, which can lead to symptoms such as fatigue, nausea, and confusion. ALP is an enzyme that is produced by bone cells, and its levels can be elevated in the presence of bone metastases.

A common diagnostic tool for bone metastases is an isotope bone scan, which uses technetium-99m labelled diphosphonates that accumulate in the bones. The scan can show multiple irregular foci of high-grade activity in the bones, indicating the presence of metastatic cancer. In the image provided, the bone scan shows multiple osteoblastic metastases in a patient with metastatic prostate cancer.

The superior mesenteric lymph nodes are responsible for draining the duodenum, which is the second section of the gastrointestinal system. This lymphatic drainage is important for staging gastrointestinal cancers, and is similar to the blood supply of the gut. While the coeliac lymph nodes drain the first part of the gastrointestinal system, the inferior mesenteric lymph nodes drain the third part, and the internal iliac lymph nodes drain the lower part of the rectum and some of the anal canal. The para-aortic lymph nodes are not involved in the drainage of the gastrointestinal system, but instead drain the genito-urinary system. It is important to understand the correct lymphatic drainage patterns for accurate cancer staging.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

The inheritance of Haemophilia A and B is crucial in identifying individuals who are at risk of developing the condition. Haemophilia A and B are genetic disorders that are inherited in an X-linked recessive manner. Haemophilia A is caused by a deficiency in clotting factor VIII, while haemophilia B is caused by a deficiency in clotting factor IX.

On the other hand, haemophilia C, which is caused by a deficiency in clotting factor XI, is primarily inherited in an autosomal recessive manner. In X-linked recessive conditions like haemophilia B, males are more likely to be affected than females. This is because males only need one abnormal copy of the gene, which is carried on the X chromosome, to be affected.

Females, on the other hand, can be carriers of the condition if they carry one normal and one abnormal copy of the gene. While carriers can have clotting abnormalities, these are usually milder than those seen in affected individuals. Men cannot pass the condition to their sons, but they will pass on the abnormal X chromosome to all their daughters, who will be carriers.

Female carriers can pass on the condition to around half their sons, and half their daughters will be carriers. Females can only be affected if they are the offspring of an affected male and a carrier female. In summary, the inheritance of haemophilia A and B is crucial in identifying individuals who are at risk of developing the condition. It also helps in providing appropriate genetic counseling and management for affected individuals and their families.

The translocation of chromosomes is associated with various types of lymphoma and leukaemia. For example, the t(14;18) translocation causes follicular lymphoma by increasing BCL-2 transcription. Similarly, the t(8;14) translocation causes Burkitt lymphoma, while the t(9;22) translocation leads to the Philadelphia chromosome and chronic myeloid leukaemia. Mantle cell lymphoma is associated with the t(11;14) translocation. These translocations can help diagnose and classify these haematological malignancies.

Genetics of Haematological Malignancies

Haematological malignancies are cancers that affect the blood, bone marrow, and lymphatic system. These cancers are often associated with specific genetic abnormalities, such as translocations. Here are some common translocations and their associated haematological malignancies:

– Philadelphia chromosome (t(9;22)): This translocation is present in more than 95% of patients with chronic myeloid leukaemia (CML). It results in the fusion of the Abelson proto-oncogene with the BCR gene on chromosome 22, creating the BCR-ABL gene. This gene codes for a fusion protein with excessive tyrosine kinase activity, which is a poor prognostic indicator in acute lymphoblastic leukaemia (ALL).

– t(15;17): This translocation is seen in acute promyelocytic leukaemia (M3) and involves the fusion of the PML and RAR-alpha genes.

– t(8;14): Burkitt’s lymphoma is associated with this translocation, which involves the translocation of the MYC oncogene to an immunoglobulin gene.

– t(11;14): Mantle cell lymphoma is associated with the deregulation of the cyclin D1 (BCL-1) gene.

– t(14;18): Follicular lymphoma is associated with increased BCL-2 transcription due to this translocation.

Understanding the genetic abnormalities associated with haematological malignancies is important for diagnosis, prognosis, and treatment.

GVHD occurs when T cells from the donor tissue attack the recipient’s cells. This often manifests as skin and gastrointestinal symptoms in a host who lacks T cells, following a bone marrow or stem cell transplant. The immune response is initiated by donor CD4+ T cells recognizing the recipient’s MHC II as foreign, while donor CD8+ T cells cause tissue damage.

Understanding Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can occur after bone marrow or solid organ transplantation. It happens when the T cells in the donor tissue attack the recipient’s cells. This is different from transplant rejection, where the recipient’s immune cells attack the donor tissue. GVHD is diagnosed using the Billingham criteria, which require that the transplanted tissue contains functioning immune cells, the donor and recipient are immunologically different, and the recipient is immunocompromised.

The incidence of GVHD varies, but it can occur in up to 50% of patients who receive allogeneic bone marrow transplants. Risk factors include poorly matched donor and recipient, the type of conditioning used before transplantation, gender disparity between donor and recipient, and the source of the graft.

Acute and chronic GVHD are considered separate syndromes. Acute GVHD typically occurs within 100 days of transplantation and affects the skin, liver, and gastrointestinal tract. Chronic GVHD may occur after acute disease or arise de novo and has a more varied clinical picture.

Diagnosis of GVHD is largely clinical and based on the exclusion of other pathology. Signs and symptoms of acute GVHD include a painful rash, jaundice, diarrhea, nausea, vomiting, and fever. Chronic GVHD can affect the skin, eyes, gastrointestinal tract, and lungs.

Treatment of GVHD involves immunosuppression and supportive measures. Intravenous steroids are the mainstay of treatment for severe cases of acute GVHD, while extended courses of steroid therapy are often needed in chronic GVHD. Second-line therapies include anti-TNF, mTOR inhibitors, and extracorporeal photopheresis. Topical steroid therapy may be sufficient in mild disease with limited cutaneous involvement. However, excessive immunosuppression may increase the risk of infection and limit the beneficial graft-versus-tumor effect of the transplant.

There are five potential disease phenotypes of alpha thalassaemia based on the number of faulty or missing globin alleles in a patient’s genotype. These include silent carrier (alpha(+) heterozygous) for one missing allele, alpha thalassaemia trait: alpha(0) heterozygous for two missing alleles, alpha thalassaemia trait: alpha(+) homozygous for two missing alleles, haemoglobin H disease for three missing alleles, and (–/–) for four missing alleles.

Understanding Alpha-Thalassaemia

Alpha-thalassaemia is a genetic disorder that results from a deficiency of alpha chains in haemoglobin. The condition is caused by a mutation in the alpha-globulin genes located on chromosome 16. The severity of the disease depends on the number of alpha globulin alleles affected. If one or two alleles are affected, the blood picture would be hypochromic and microcytic, but the haemoglobin level would typically be normal. However, if three alleles are affected, it results in a hypochromic microcytic anaemia with splenomegaly, which is known as Hb H disease. In the case of all four alleles being affected, which is known as homozygote, it can lead to death in utero, also known as hydrops fetalis or Bart’s hydrops. Understanding the different levels of severity of alpha-thalassaemia is crucial in diagnosing and managing the condition.

Factors Associated with Positive Long-Term Outcome in Leukemia Patients

Leukemia patients who are younger than 30 years old, have a white blood cell count of less than 30 ×109/L, and have a mediastinal mass are more likely to have a favorable long-term outcome. Additionally, those with a T cell or TMy immunophenotype and do not have the Philadelphia (Ph) chromosome also have a better prognosis. These clinical and biologic features are important factors to consider when assessing the potential outcome for leukemia patients. Proper identification and monitoring of these factors can aid in the development of effective treatment plans and improve patient outcomes.

Hb SC is a less severe variant of sickle cell disease that can be detected early through screening of children in the UK. This condition is characterized by the presence of both the sickle mutation and the HbC mutation, which results in a lysine substitution for glutamic acid on position 6 of the beta chain. While HbSC shares similarities with sickle cell disease, its symptoms are less frequent and severe. The severity of the disease can vary depending on the specific genotype, with HbAA being normal, HbAS being asymptomatic, HbSC/Sβ+ being moderately affected, and HbSS/Sβ0 being severely affected due to the absence of normal haemoglobin.

Understanding Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic disorder that occurs when an abnormal haemoglobin chain, known as HbS, is synthesized due to an autosomal recessive condition. This condition is more common in people of African descent, as the heterozygous condition offers some protection against malaria. In the UK, around 10% of Afro-Caribbean individuals are carriers of HbS. Symptoms in homozygotes typically do not develop until 4-6 months when the abnormal HbSS molecules take over from fetal haemoglobin.

The pathophysiology of sickle-cell anaemia involves the substitution of the polar amino acid glutamate with the non-polar valine in each of the two beta chains (codon 6) of haemoglobin. This substitution decreases the water solubility of deoxy-Hb, causing HbS molecules to polymerize and sickle in the deoxygenated state. HbAS patients sickle at p02 2.5 – 4 kPa, while HbSS patients sickle at p02 5 – 6 kPa. Sickle cells are fragile and can cause haemolysis, block small blood vessels, and lead to infarction.

To diagnose sickle-cell anaemia, haemoglobin electrophoresis is the definitive test. It is essential to understand the pathophysiology and symptoms of sickle-cell anaemia to provide appropriate care and management for affected individuals.

Genetics of Haematological Malignancies

Haematological malignancies are cancers that affect the blood, bone marrow, and lymphatic system. These cancers are often associated with specific genetic abnormalities, such as translocations. Here are some common translocations and their associated haematological malignancies:

– Philadelphia chromosome (t(9;22)): This translocation is present in more than 95% of patients with chronic myeloid leukaemia (CML). It results in the fusion of the Abelson proto-oncogene with the BCR gene on chromosome 22, creating the BCR-ABL gene. This gene codes for a fusion protein with excessive tyrosine kinase activity, which is a poor prognostic indicator in acute lymphoblastic leukaemia (ALL).

– t(15;17): This translocation is seen in acute promyelocytic leukaemia (M3) and involves the fusion of the PML and RAR-alpha genes.

– t(8;14): Burkitt’s lymphoma is associated with this translocation, which involves the translocation of the MYC oncogene to an immunoglobulin gene.

– t(11;14): Mantle cell lymphoma is associated with the deregulation of the cyclin D1 (BCL-1) gene.

– t(14;18): Follicular lymphoma is associated with increased BCL-2 transcription due to this translocation.

Understanding the genetic abnormalities associated with haematological malignancies is important for diagnosis, prognosis, and treatment.

JAK2 Mutation and Primary Polycythaemia

Polycythaemia is a condition characterized by an increase in the number of red blood cells in the body. In primary polycythaemia, over 95% of cases are associated with a mutation in the JAK2 pathway. This mutation causes the pathway to be constantly active, leading to the production of red blood cells even in the absence of erythropoietin (EPO). The most common mutation occurs in exon 12, affecting position V617F.

On the other hand, secondary causes of polycythaemia include COPD and smoking, which lower blood oxygenation and trigger the secretion of EPO by the kidney’s peritubular cells. ADPKD also promotes the secretion of increased EPO, resulting in the production and release of more red blood cells. Dehydration, on the other hand, reduces plasma volume, leading to an apparent/relative polycythaemia. While these factors can cause an increase in red blood cells, they are not associated with a primary haematological disorder like the JAK2 mutation.

When bronchogenic carcinoma leads to SVC obstruction, patients usually experience dyspnea, cough, and swelling of the face.

Understanding Superior Vena Cava Obstruction

Superior vena cava obstruction is a medical emergency that occurs when the superior vena cava, a large vein that carries blood from the upper body to the heart, is compressed. This condition is commonly associated with lung cancer, but it can also be caused by other malignancies, aortic aneurysm, mediastinal fibrosis, goitre, and SVC thrombosis. The most common symptom of SVC obstruction is dyspnoea, but patients may also experience swelling of the face, neck, and arms, headache, visual disturbance, and pulseless jugular venous distension.

The management of SVC obstruction depends on the underlying cause and the patient’s individual circumstances. Endovascular stenting is often the preferred treatment to relieve symptoms, but certain malignancies may require radical chemotherapy or chemo-radiotherapy instead. Glucocorticoids may also be given, although the evidence supporting their use is weak. It is important to seek advice from an oncology team to determine the best course of action for each patient.

Rivaroxaban is a direct inhibitor of factor Xa, which is the correct answer. Pulmonary emboli can be caused by various factors, and symptoms include chest pain, dyspnoea, and haemoptysis. Factor Xa inhibitors, such as rivaroxaban, have replaced warfarin as the first-line treatment for stroke prevention in patients with atrial fibrillation.

Dabigatran is a direct thrombin inhibitor and has a different mechanism of action compared to rivaroxaban. It is commonly used for venous thromboembolism prophylaxis after total knee or hip replacement surgery.

Dalteparin is a type of low molecular weight heparin (LMWH) and has a different mechanism of action compared to factor Xa inhibitors. It is used for prophylaxis against venous thromboembolism in patients who are immobile or have recently had surgery.

Fondaparinux is an indirect inhibitor of factor Xa and is not the correct answer. It is used for the treatment of deep-vein thrombosis, pulmonary embolism, and acute coronary syndrome.

Direct oral anticoagulants (DOACs) are medications used to prevent stroke in non-valvular atrial fibrillation (AF), as well as for the prevention and treatment of venous thromboembolism (VTE). To be prescribed DOACs for stroke prevention, patients must have certain risk factors, such as a prior stroke or transient ischaemic attack, age 75 or older, hypertension, diabetes mellitus, or heart failure. There are four DOACs available, each with a different mechanism of action and method of excretion. Dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. The majority of DOACs are excreted either through the kidneys or the liver, with the exception of apixaban and edoxaban, which are excreted through the feces. Reversal agents are available for dabigatran and rivaroxaban, but not for apixaban or edoxaban.

Schistocytes on a blood film are indicative of intravascular haemolysis, which is the most likely cause in this clinical scenario. The presence of a mid-line sternotomy scar, metallic click to the first heart sound, and warfarin prescription suggests a metal heart valve, which can cause sheering of red blood cells and subsequent intravascular haemolysis. Vasculitis, thrombotic thrombocytopenic purpura (TTP), and B12 deficiency are less likely causes in this case.

Pathological Red Cell Forms in Blood Films

Blood films are used to examine the morphology of red blood cells and identify any abnormalities. Pathological red cell forms are associated with various conditions and can provide important diagnostic information. Some of the common pathological red cell forms include target cells, tear-drop poikilocytes, spherocytes, basophilic stippling, Howell-Jolly bodies, Heinz bodies, schistocytes, pencil poikilocytes, burr cells (echinocytes), and acanthocytes.

Target cells are seen in conditions such as sickle-cell/thalassaemia, iron-deficiency anaemia, hyposplenism, and liver disease. Tear-drop poikilocytes are associated with myelofibrosis, while spherocytes are seen in hereditary spherocytosis and autoimmune hemolytic anaemia. Basophilic stippling is a characteristic feature of lead poisoning, thalassaemia, sideroblastic anaemia, and myelodysplasia. Howell-Jolly bodies are seen in hyposplenism, while Heinz bodies are associated with G6PD deficiency and alpha-thalassaemia. Schistocytes or ‘helmet cells’ are seen in conditions such as intravascular haemolysis, mechanical heart valve, and disseminated intravascular coagulation. Pencil poikilocytes are seen in iron deficiency anaemia, while burr cells (echinocytes) are associated with uraemia and pyruvate kinase deficiency. Acanthocytes are seen in abetalipoproteinemia.

In addition to these red cell forms, hypersegmented neutrophils are seen in megaloblastic anaemia. Identifying these pathological red cell forms in blood films can aid in the diagnosis and management of various conditions.

The upper limb drains into the axillary lymph nodes, which can become painful and may lead to lymphadenitis in cases of secondary bacterial infection. The correct dermatome for sensory innervation of the lateral half of the forearm is C6, while C2 provides sensory innervation to the posterior half of the head, L2 to the anterior thighs, and T8 to a horizontal band around the torso below the umbilicus (T10), all of which are drained by different lymph nodes.

Lymphatic drainage is the process by which lymphatic vessels carry lymph, a clear fluid containing white blood cells, away from tissues and organs and towards lymph nodes. The lymphatic vessels that drain the skin and follow venous drainage are called superficial lymphatic vessels, while those that drain internal organs and structures follow the arteries and are called deep lymphatic vessels. These vessels eventually lead to lymph nodes, which filter and remove harmful substances from the lymph before it is returned to the bloodstream.

The lymphatic system is divided into two main ducts: the right lymphatic duct and the thoracic duct. The right lymphatic duct drains the right side of the head and right arm, while the thoracic duct drains everything else. Both ducts eventually drain into the venous system.

Different areas of the body have specific primary lymph node drainage sites. For example, the superficial inguinal lymph nodes drain the anal canal below the pectinate line, perineum, skin of the thigh, penis, scrotum, and vagina. The deep inguinal lymph nodes drain the glans penis, while the para-aortic lymph nodes drain the testes, ovaries, kidney, and adrenal gland. The axillary lymph nodes drain the lateral breast and upper limb, while the internal iliac lymph nodes drain the anal canal above the pectinate line, lower part of the rectum, and pelvic structures including the cervix and inferior part of the uterus. The superior mesenteric lymph nodes drain the duodenum and jejunum, while the inferior mesenteric lymph nodes drain the descending colon, sigmoid colon, and upper part of the rectum. Finally, the coeliac lymph nodes drain the stomach.

Haemophilia A is characterized by prolonged APTT and reduced levels of factor 8:C, while bleeding time and PT remain normal. Cholestatic jaundice hinders the absorption of vitamin K, which is fat-soluble. Patients who undergo massive transfusions, equivalent to more than 10 units of blood or their entire blood volume, are at risk of thrombocytopenia, as well as deficiencies in factor 5 and 8.

Abnormal coagulation can be caused by various factors such as heparin, warfarin, disseminated intravascular coagulation (DIC), and liver disease. Heparin prevents the activation of factors 2, 9, 10, and 11, while warfarin affects the synthesis of factors 2, 7, 9, and 10. DIC affects factors 1, 2, 5, 8, and 11, and liver disease affects factors 1, 2, 5, 7, 9, 10, and 11.

When interpreting blood clotting test results, different disorders can be identified based on the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), and bleeding time. Haemophilia is characterized by increased APTT levels, normal PT levels, and normal bleeding time. On the other hand, von Willebrand’s disease is characterized by increased APTT levels, normal PT levels, and increased bleeding time. Lastly, vitamin K deficiency is characterized by increased APTT and PT levels, and normal bleeding time. Proper interpretation of these results is crucial in diagnosing and treating coagulation disorders.

The standard chemotherapy regimen for non-Hodgkin lymphoma is R-CHOP, which includes Rituximab (in certain patients), cyclophosphamide, hydroxydaunorubicin, Oncovin (vincristine), and prednisolone. However, one of the significant side effects of vincristine is chemotherapy-induced peripheral neuropathy, which can cause tingling or numbness starting from the extremities. It can also lead to severe neuropathic pain and distal weakness, such as foot drop.

While Rituximab can cause adverse effects such as cardiotoxicity and infections, it is not commonly associated with neurological effects. Cyclophosphamide, on the other hand, can cause chemotherapy-induced nausea and vomiting, bone marrow suppression, and haemorrhagic cystitis due to its toxicity to the bladder epithelium.

Hydroxydaunorubicin is known to cause dilated cardiomyopathy, which can lead to heart failure and has a high mortality rate.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

The correct mechanism of acute haemolytic transfusion reactions is the destruction of ABO-incompatible red blood cells (RBCs) by host IgM antibodies. These reactions typically occur due to human error in giving patients ABO-incompatible blood products. Symptoms include hypotension, fever, and abdominal and/or chest pain.

Fluid overload, host anti-IgA antibodies reacting against donor IgA, and host antibodies reacting with donor white cell fragments are all incorrect mechanisms for acute haemolytic transfusion reactions. These mechanisms are associated with transfusion-associated circulatory overload (TACO), anaphylaxis to blood products in patients with IgA deficiency, and non-haemolytic febrile reactions, respectively. These conditions present with different symptoms and are not associated with the rapid onset of hypotension and abdominal pain seen in acute haemolytic transfusion reactions.

Blood product transfusion complications can be categorized into immunological, infective, and other complications. Immunological complications include acute haemolytic reactions, non-haemolytic febrile reactions, and allergic/anaphylaxis reactions. Infective complications may arise due to transmission of vCJD, although measures have been taken to minimize this risk. Other complications include transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), hyperkalaemia, iron overload, and clotting.

Non-haemolytic febrile reactions are thought to be caused by antibodies reacting with white cell fragments in the blood product and cytokines that have leaked from the blood cell during storage. These reactions may occur in 1-2% of red cell transfusions and 10-30% of platelet transfusions. Minor allergic reactions may also occur due to foreign plasma proteins, while anaphylaxis may be caused by patients with IgA deficiency who have anti-IgA antibodies.

Acute haemolytic transfusion reaction is a serious complication that results from a mismatch of blood group (ABO) which causes massive intravascular haemolysis. Symptoms begin minutes after the transfusion is started and include a fever, abdominal and chest pain, agitation, and hypotension. Treatment should include immediate transfusion termination, generous fluid resuscitation with saline solution, and informing the lab. Complications include disseminated intravascular coagulation and renal failure.

TRALI is a rare but potentially fatal complication of blood transfusion that is characterized by the development of hypoxaemia/acute respiratory distress syndrome within 6 hours of transfusion. On the other hand, TACO is a relatively common reaction due to fluid overload resulting in pulmonary oedema. As well as features of pulmonary oedema, the patient may also be hypertensive, a key difference from patients with TRALI.

The Thymus Gland: Development, Structure, and Function

The thymus gland is an encapsulated organ that develops from the third and fourth pharyngeal pouches. It descends to the anterior superior mediastinum and is subdivided into lobules, each consisting of a cortex and a medulla. The cortex is made up of tightly packed lymphocytes, while the medulla is mostly composed of epithelial cells. Hassall’s corpuscles, which are concentrically arranged medullary epithelial cells that may surround a keratinized center, are also present.

The inferior parathyroid glands, which also develop from the third pharyngeal pouch, may be located with the thymus gland. The thymus gland’s arterial supply comes from the internal mammary artery or pericardiophrenic arteries, while its venous drainage is to the left brachiocephalic vein. The thymus gland plays a crucial role in the development and maturation of T-cells, which are essential for the immune system’s proper functioning.

The presence of factor V Leiden mutation leads to resistance to activated protein C.

The most probable cause of the patient’s recurrent DVTs and family history of thrombo-embolic events is factor V Leiden, which is the most common inherited thrombophilia. This mutation results in activated protein C resistance, as activated factor V is not inactivated as efficiently by protein C.

Antiphospholipid syndrome is an acquired thrombophilia that can cause both arterial and venous thromboses, and may present with thrombocytopenia. However, the patient’s positive family history and normal full blood count make this diagnosis less likely than factor V Leiden.

Protein C deficiency, protein S deficiency, and antithrombin III deficiency are all inherited thrombophilias, but they are less prevalent in the population compared to factor V Leiden. Therefore, they are less likely to be the underlying cause of the patient’s symptoms.

Understanding Factor V Leiden

Factor V Leiden is a common inherited thrombophilia, affecting around 5% of the UK population. It is caused by a mutation in the Factor V Leiden protein, resulting in activated factor V being inactivated 10 times more slowly by activated protein C than normal. This leads to activated protein C resistance, which increases the risk of venous thrombosis. Heterozygotes have a 4-5 fold risk of venous thrombosis, while homozygotes have a 10 fold risk, although the prevalence of homozygotes is much lower at 0.05%.

Despite its prevalence, screening for Factor V Leiden is not recommended, even after a venous thromboembolism. This is because a previous thromboembolism itself is a risk factor for further events, and specific management should be based on this rather than the particular thrombophilia identified.

Other inherited thrombophilias include Prothrombin gene mutation, Protein C deficiency, Protein S deficiency, and Antithrombin III deficiency. The table below shows the prevalence and relative risk of venous thromboembolism for each of these conditions.

Overall, understanding Factor V Leiden and other inherited thrombophilias can help healthcare professionals identify individuals at higher risk of venous thrombosis and provide appropriate management to prevent future events.

Condition | Prevalence | Relative risk of VTE
— | — | —
Factor V Leiden (heterozygous) | 5% | 4
Factor V Leiden (homozygous) | 0.05% | 10
Prothrombin gene mutation (heterozygous) | 1.5% | 3
Protein C deficiency | 0.3% | 10
Protein S deficiency | 0.1% | 5-10
Antithrombin III deficiency | 0.02% | 10-20